/
BLCO
$16.56-$0.07 (-0.42%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$5.8B
357M shares
52-week range
$12.41 – $18.92
64% from low
Sector
OPHTHALMIC GOODS
Exchange
NYSE
CS
Borrow rate
0.73%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-3.44
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.67B | $3.78B | $3.41B | $3.77B | $3.77B | $4.15B | $4.79B | $5.10B |
| Cost of revenue | $1.31B | $1.33B | $1.28B | $1.47B | $1.52B | $1.64B | $1.87B | $2.31B |
| Gross profit | $2.35B | $2.45B | $2.13B | $2.30B | $2.25B | $2.50B | $2.92B | $2.79B |
| Gross margin | 64.2% | 64.9% | 62.3% | 61.0% | 59.7% | 60.4% | 60.9% | 54.8% |
| R&D | $221.0M | $258.0M | $281.0M | $271.0M | $307.0M | $324.0M | $343.0M | $371.0M |
| Operating income | $416.0M | $396.0M | $260.0M | $329.0M | $207.0M | $130.0M | $162.0M | $188.0M |
| EBITDA | $922.0M | $936.0M | $732.0M | $733.0M | $598.0M | $499.0M | $601.0M | $535.0M |
| Net income | $710.0M | $298.0M | −$18.0M | $182.0M | $6.0M | −$260.0M | −$317.0M | −$360.0M |
| Net margin | 19.4% | 7.9% | -0.5% | 4.8% | 0.2% | -6.3% | -6.6% | -7.1% |
| EPS (diluted) | 2.03 | 0.85 | -0.05 | 0.52 | 0.04 | -0.74 | -0.90 | -1.02 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $5.5B | $0.81 | $0.80–$0.81 | 7 |
| 2027 | $5.8B | $1.07 | $0.93–$1.21 | 7 |
| 2028 | $6.1B | $1.38 | $0.92–$1.69 | 3 |
| 2029 | $5.9B | $1.78 | $1.77–$1.79 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$8.70
Price
$16.56
Implied downside
-47%
Peer comparison
Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
www.bausch.com- Employees
- 13,000
- IPO / List date
- May 6, 2022
- HQ
- VAUGHAN, A6
Held by traders on TradeandTell
No one on the platform currently holds BLCO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-03-31 | 63,000 | $913.5K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BLCO yet.
